Prime Medicine (NASDAQ:PRME) Upgraded at Lifesci Capital

Lifesci Capital upgraded shares of Prime Medicine (NASDAQ:PRME) to a strong-buy rating in a research report report published on Tuesday morning,Zacks.com reports.

Other equities research analysts also recently issued reports about the company. Weiss Ratings restated a “sell (d-)” rating on shares of Prime Medicine in a report on Monday. Wall Street Zen lowered shares of Prime Medicine from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. One investment analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy”.

Prime Medicine Price Performance

Shares of PRME stock opened at $3.57 on Tuesday. The business has a fifty day moving average price of $4.11. The firm has a market cap of $644.42 million, a price-to-earnings ratio of -2.48 and a beta of 2.69. Prime Medicine has a 12 month low of $1.11 and a 12 month high of $6.94.

Prime Medicine (NASDAQ:PRME) last announced its earnings results on Friday, November 7th. The company reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.04). Prime Medicine had a negative net margin of 3,301.64% and a negative return on equity of 163.51%. The business had revenue of $1.23 million for the quarter.

About Prime Medicine

We are a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, Prime Editors, to address the widest spectrum of diseases by deploying our Prime Editing technology, which we believe is a versatile, precise, efficient and broad gene editing technology. Genetic mutations implicated in disease are diverse and can range from errors of a single base, known as point mutations, to errors that extend beyond a single base, such as insertions, deletions, duplications, or combinations thereof.